var tipuesearch = {"pages": [{
    "title": "The 1st 5 Minutes",
    "text": "ACS MONA Morphine 2-4mg IV q5-30min in increments of 2-8mg PRN BP and RR after each bolus Can consider meperidine or other opiod D/C all NSAIDs and avoid all NSAIDs during admission O2 to sat of 95% if &lt; 90% on presentation SL NTG 0.4mg q5min x3, if non-responsive start IV NTG 5-10mcg/min to 75-100mcg/min (Max 200, consider 1-2min bolus of 400mcg/min to load) Verify NO PDEIs w/i 24-36hr IV Contraindicated w/ SBP &lt; 90; &gt; 30 mmHg change from baseline; Bradycardia or Tachycardia; Suspected RV Infarction Monitor BP and HR q2h while on IV ASA 325mg Chewed and Swallowed on presentation Consider anxiolytics to decrease HR and demand Consider PCI for STEMI Consult ACS for further management Stroke Labs Conduct NIHSS (National Institutes of Health Stroke Scale) Head CT to r/o hemorrhagic stroke Monitor BP / O2Sat BG BMP CBC INR / aPTT EKG Echo Pt is NPO until swallow study conducted Initial Therapies Manage BG if abnormal Hypoglycemia can result in stroke SSx Hyperglycemia above 180 mg/dL can result in higher morbidity / mortality Consider thrombolytics for ischemic strokes (must r/o hemorrhagic) Manage HTN to &lt; 220/120 for non-thrombolytic pts, &lt; 180/105 for thrombolysis IV antihypertensives warranted, do not lower BP excessively, as elevated BP may help perfuse partially occluded areas Agressive BP control can limit stroke recurrence, long-term neuro deficits, an decrease risk of cerebral edema; however concern from above usually wins, attempt to balance (i.e 150s instead of 170s or 110s) Thrombolysis Dosing Must satisfy inclusion / exclusion criteria below 0.9 mg/kg NTE 90mg Total dose 10% (0.09 mg/kg) IVPB over 1min 90% (0.81 mg/kg) IV over 60min Give w/i 60min of arrival Keep BP &lt; 180/105 Monitor q15min x2h then q30min x 6h then q1h x16hr Can begin to lower to outpt goal after 24h Avoid all antiplatelets and anticoagulants for 24hr post-admin SEs Bleeding Stroke Conversion Cerebral Edema Inclusion Criteria Ischemic stroke confirmed by imaging &lt; 3hrs from SSx onset Extended interval available, see below Some evidence for imaging-based determination of thrombolysis eligbility here, but not currently in guidelines ≥ 18yo Exclusion Criteria Evidence of active internal bleed Hx of intracranial hemorrhage Previous stroke or head trauma in less than 3mo GI or GU hemorrhage in ≤ 21d Major surgery in ≤ 14d MI in ≤ 3mo BP &gt; 185/110 at administration time BG &lt; 50 mg/dL Plt &lt; 100k Current anticoag w/ INR &gt; 1.7 or aPTT &gt; 45s NOACs CI tPA Reversible exclusion criteria Extended tPA Window &lt; 4.5hrs after SSx onset Add the following to the exclusion criteria Age ≥ 80 Hx of Stroke w/ DM Any recent anticoag use NIHSS &gt; 25 BP Control Use common IV antihypertensives discussed in HTN Crisis section Labetalol 10-20mg IVPB q10-20min NTE 300mg Nicardipine 5mg/hr IV titrated q5min NTE 15 mg/hr Nitroprusside 0.5-10 mcg/kg/min titrated (preferable if DBP &gt; 140) Transfusion for Severe Acute Anemia Criteria Acutely Symptomatic Hgb &lt; 8 (some argue 7) Admin PRBCs Type and cross before admin 1 U &amp;approx; 300 mL &amp;approx; Δ 1 g/dL Hgb Consider activation of massive transfusion protocol Hemorrhaging / trauma pts may require infusions of FFP and Plt as well to sustain coagulation, strongly consider before using large volumes of crystalloid Pts refusing transfusion can be given high dose iron, B12, and Epo, look up protocol Complications Iron Overload Infection (HIV etc, rare) Hyperviscosity syndrome Alloimmunization Volume overload Transfusion reactions",
    "tags": "",
    "url": "/peripheral_brain/firstFive"
  },{
    "title": "Formulas",
    "text": "Dosing and Body Weights Acid-Base Nitrogen Balance Fluids and Electrolytes Anticoagulation EKG Interpretation Pharmacokinetics General PK 1-Compartment Model",
    "tags": "",
    "url": "/peripheral_brain/formulas"
  },{
    "title": "Lab Values",
    "text": "ABG pH / paCO2 / paO2 / [HCO3]- / O2 Sat Lab Low High Units pH 7.35 7.45 n/a paCO2 35 45 mmHg paO2 80 100 mmHg HCO3- 22 26 mEq/L O2 Sat 95% 100% % Saturation Electrolytes Lab Low High Units pH 7.35 7.45 n/a Na+ 135 145 mEq/L Cl- 95 105 mEq/L K+ 3.5 5 mEq/L Ca2+ 8.5 10.5 mg/dL Ionized Ca2+ 4.6 5.1 mg/dL HCO3- 22 26 mEq/L Mg2+ 1.5 2.5 mg/dL PO43- 2.5 4.5 mg/dL Osm 275 290 mOsm/L Anion Gap 3 11 mEq/L Chem7 Na K Cl Bicarb BUN SCr Gluc Hematology WBC Plt Hgb Hct Lab Low High Unit Hgb (M) 13.5 17.5 g/dL Hgb (F) 12 16 g/dL Hct (M) 41 53 % Hct (F) 36 46 % RBC (M) 4.5 5.9 M/mcL RBC (F) 4.1 5.1 M/mcL MCV 80 100 fL RDW 11 15 % Folate 1.8 16 ng/mL B12 100 900 pg/mL Cells Low % High % Segmented 45 75 Bands 3 5 Lymphocytes 20 40 Monocytes 2 8 Eosinophils 0 4 Basophils 2 2 Lab Low High Unit Ferritin 10 20 mcg/L Serum Iron 60 150 mcg/dL Transferrin 20 50 % TIBC 250 400 mcg/dL Anticoagulation Monitoring Test Evaluating Low High Units Platelet Count Bone Marrow 150 450 k/mm3 PT Extrinsic Pathway 12 14 sec INR Extrinsic Pathway - 1.1 n/a aPTT Intrinsic Pathway 26 33 sec EKG Normal Values Measure Interval (ms) PR Interval 120-200 QRS 80-120 QT* 380-460 QTc (Male)* 360-470 QTc (Female)* 360-480 *High risk of Torsades w/ QTc ≥500ms",
    "tags": "",
    "url": "/peripheral_brain/lab_values"
  },{
    "title": "Sources",
    "text": "Cardiology ACS AHA NSTE-ACS Guidelines 2014 [^amsterdam2014]: Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017 AHA STEMI Guidelines [^ogara2013]: O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. *Journal of the American College of Cardiology*. 2013;61(4):e78-e140. doi:[10.1016/j.jacc.2012.11.019](https://doi.org/10.1016/j.jacc.2012.11.019) Benign Early Repol vs Subtle LAD STEMI (4-variable) [^driver2017]: Driver BE, Khalil A, Henry T, Kazmi F, Adil A, Smith SW. A new 4-variable formula to differentiate normal variant ST segment elevation in V2-V4 (early repolarization) from subtle left anterior descending coronary occlusion - Adding QRS amplitude of V2 improves the model. *Journal of Electrocardiology*. 2017;50(5):561-569. doi:[10.1016/j.jelectrocard.2017.04.005](https://doi.org/10.1016/j.jelectrocard.2017.04.005) DAPT Duration in CAD [^levine2016]: Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. *Journal of the American College of Cardiology*. 2016;68(10):1082-1115. doi:[10.1016/j.jacc.2016.03.513](https://doi.org/10.1016/j.jacc.2016.03.513) LBBB vs STEMI [^smith2012]: Smith SW, Dodd KW, Henry TD, Dvorak DM, Pearce LA. Diagnosis of ST-Elevation Myocardial Infarction in the Presence of Left Bundle Branch Block With the ST-Elevation to S-Wave Ratio in a Modified Sgarbossa Rule. *Annals of Emergency Medicine*. 2012;60(6):766-776. doi:[10.1016/j.annemergmed.2012.07.119](https://doi.org/10.1016/j.annemergmed.2012.07.119) Third Universal MI Definition [^thygesen]: Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third Universal Definition of Myocardial Infarction. :16. STEMI PCI Update [^levine2015]: Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction. *Journal of the American College of Cardiology*. 2016;67(10):1235-1250. doi:[10.1016/j.jacc.2015.10.005](https://doi.org/10.1016/j.jacc.2015.10.005) HTN AHA HTN Guidelines [^whelton2018]: Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. *Journal of the American College of Cardiology*. 2018;71(19):e127-e248. doi:[10.1016/j.jacc.2017.11.006](https://doi.org/10.1016/j.jacc.2017.11.006) VTE VTE Treatment Guidelines [^kearon2016]: Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease. Chest. 2016;149(2):315-352. doi:[10.1016/j.chest.2015.11.026](https://doi.org/10.1016/j.chest.2015.11.026) VTE Prophylaxis [^gould2012]: Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in Nonorthopedic Surgical Patients. Chest. 2012;141(2):e227S-e277S. doi:[10.1378/chest.11-2297](https://doi.org/10.1378/chest.11-2297) CHF [^yancy2013]: Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;128(16). doi:[10.1161/CIR.0b013e31829e8776](https://doi.org/10.1161/CIR.0b013e31829e8776) [^yancy2017]: Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. *Journal of the American College of Cardiology*. 2017;70(6):776-803. doi:[10.1016/j.jacc.2017.04.025 Critical Care Hypotension Management Push-Dose Pressors [^weingart2015]: Weingart S. Push-dose pressors for immediate blood pressure control. *Clinical and Experimental Emergency Medicine*. 2015;2(2):131-132. doi:[10.15441/ceem.15.010](https://doi.org/10.15441/ceem.15.010) [^hollenberg2011]: Hollenberg SM. Vasoactive Drugs in Circulatory Shock. American Journal of Respiratory and Critical Care Medicine. 2011;183(7):847-855. doi:[10.1164/rccm.201006-0972CI](https://doi.org/10.1164/rccm.201006-0972CI) [^jentzer2015]: Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. Journal of Cardiovascular Pharmacology and Therapeutics. 2015;20(3):249-260. doi:[10.1177/1074248414559838](https://doi.org/10.1177/1074248414559838) [^overgaard2008]: Overgaard CB, Džavík V. Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease. Circulation. 2008;118(10):1047-1056. doi:[10.1161/CIRCULATIONAHA.107.728840](https://doi.org/10.1161/CIRCULATIONAHA.107.728840) ID Vancomycin Dosing Optimizing Vancomycin Dosing [^deryke2009]: Deryke CA, Alexander DP. Optimizing Vancomycin Dosing through Pharmacodynamic Assessment Targeting Area under the Concentration-Time Curve/Minimum Inhibitory Concentration. *Hospital Pharmacy*. 2009;44(9):751-765. doi:[10.1310/hpj4409-751](https://doi.org/10.1310/hpj4409-751) Vancomycin PK in Renal Dysfunction [^matzkel1984]: Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. *Antimicrobial Agents and Chemotherapy*. 1984;25(4):433-437. doi:[10.1128/AAC.25.4.433](https://doi.org/10.1128/AAC.25.4.433) ASHP Vancomycin Monitoring Recommendations [^rybak2009]: Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *American Journal of Health-System Pharmacy*. 2009;66(1):82-98. doi:[10.2146/ajhp080434](https://doi.org/10.2146/ajhp080434) Aminoglycoside Dosing Stanford Health System Aminoglycoside Dosing Recommendations [^mui2017]: Mui, E. Stanford Health Care Aminoglycoside Dosing Guideline. 2017. [Link](http://med.stanford.edu/bugsanddrugs/dosing-protocols/_jcr_content/main/panel_builder/panel_0/download_2/file.res/Aminoglycoside%20Dosing%20Guide%202017-08-23.pdf) Extended Interval Aminoglycosides [^nicolau1995]: Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. *Antimicrobial Agents and Chemotherapy*. 1995;39(3):650-655. doi:[10.1128/AAC.39.3.650](https://doi.org/10.1128/AAC.39.3.650) Textbooks Pharmacology DiPiro Pharmacotherapy [^dipiro]: DiPiro JT, ed. *Pharmacotherapy: A Pathophysiologic Approach*. Tenth edition. New York: McGraw-Hill Education; 2017. Emergency Medicine Tintinalli’s [^tintinalli]: Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM, eds. *Tintinalli’s Emergency Medicine: A Comprehensive Study Guide*. Eight edition. New York: McGraw-Hill Education; 2016. Websites Drug Resources Lexicomp [^lexi]: Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: [http://online.lexi.com](http://online.lexi.com).",
    "tags": "",
    "url": "/peripheral_brain/sources"
  },{
    "title": "Test",
    "text": "Option 1 Option 2",
    "tags": "",
    "url": "/peripheral_brain/test.html"
  },{
    "title": "Antibiotic Dosing Parameters",
    "text": "Generic Loading/Maintenance Doses Drug Loading Dose Maintenance Dose (Normal Renal Fx) Gentamicin / Tobramycin 2-2.5 mg/kg 1.5-2 mg/kg q8-12hr * Amikacin 7.5 mg/kg 5-7.5 mg/kg q12hr * Vancomycin 25-30 mg/kg 15-20 mg/kg q8-12hr * (total body weight) Target Concentrations Gentamicin (Gram Negative) / Tobramycin Infection Type Peak (mg/L) Trough (mg/L) Moderate (UTIs) 4-6 ≤ 1 Moderate-Severe (Osteomyeltitis, pyelonephritis, soft-tissue infections) 6-8 ≤ 1 Severe (bacteremia, pneumonia, life-threatening infections) 8-10 ≤ 1 Gentamicin (Gram Positive) Peak: 3-5 mg/L Trough: ≤ 1 mg/L Used in combination with cell-wall active agents such as nafcillin, vancomycin, or ampicillin Amikacin Infection Type Peak (mg/L) Trough (mg/L) Moderate (UTIs) 20-25 4-8 Moderate-Severe (Osteomyeltitis, pyelonephritis, soft-tissue infections) 25-30 4-8 Severe (bacteremia, pneumonia, life-threatening infections) 25-30 4-8 Vancomycin Peak: 30-40 mg/L Trough: 10-15 mg/L (15-20 in endocarditis, osteomyelitis, meningitis, MRSA, and pneumonia) Vd: 0.6-0.7 (0.4-1) L/kg AUC0-24 / MIC = 400 AUC &gt; 700 =&gt; Increased risk of nephrotoxicity NTE 15 mg/min due to risk of Red Man Syndrome CrCl Approximate Dosing Interval (hr) 120 12 100 12-18 80 18 60 24 40 36 30 48 20 60 10 TDM Dialysis Random monitoring q3-4d and adjust Extended Interval Dosing of Aminoglycosides Use IBW if TBW &lt; 1.3 * IBW or AdjBW if TBW ≥ 1.3 * IBW Gentamicin / Tobramycin: 5-7 mg/kg, target peak of 15-20 mg/L Amikacin: 15-25 mg/kg, target peak of 50-60 mg/L Trough should be undetectable Hartford Nomogram Target Max of 20 mg/L (MIC of 2 mg/L targeting 10:1) 7 mg/kg over 1 hour (gent / tob) or 15 mg/kg (amikacin) Obtain a value 6-14hr after the start of the infusion on day 5 CrCl Interval &gt; 60 q24h 40-60 q36h 20-39 q48h &lt; 20 Use traditional *Nomogram for gent/tob; if using amikacin, divide concentration by 2 then proceed as normal",
    "tags": "",
    "url": "/peripheral_brain/calculators/abxDosingParameters.html"
  },{
    "title": "Acid-Base Analysis",
    "text": "pH paCO2 (mmHg) Bicarb (mEq/L) Base Deficit Calculated Other: Na (mEq/L) Cl (mEq/L) Lactate (mmol/L) Albumin (g/dL) Glucose (mg/dL) BUN (mg/dL) EtOH (mg/dL) Osmolality (mOsm/L) Basic Analysis pH Evaluation Pulmonary Evaluation Bicarb Evaluation Qualitative Acid-Base SID SID Evaluation Calculated Base Deficit Strong Ion Gap Strong Ion Gap Evaluation Compensation to... Chronic Resp Decrease in SID: Metabolic Acidosis Decrease in paCO2: Metabolic Alkalosis Increase in paCO2: Osmolarity Osm Osm Gap Note: All compensations will be calculated regardless of appropriate use. See the EM-Crit Acid-Base Evaluation Sheet for descriptions of these processes, as well as DDX for each Acid-Base Disorder",
    "tags": "",
    "url": "/peripheral_brain/calculators/acidBase.html"
  },{
    "title": "Aminoglycoside Initial Dosing",
    "text": "Height (in) Weight (kg) Age (yrs) SCr (mg/dL) Sex Male Female Race African American Other CrCl (mL/min) CKD-Epi CG-CrCl Other: Low Vd (L/kg) High Vd (L/kg) Volume (L) Desired Peak (mg/L) Desired Trough (mg/L) Infusion Time (hr) Max-Peak Interval (hr) Dosing Interval (hr) MD (mg) Kidney Function CG-CrCl mL/min Weight Used for CG CKD-Epi (mL/min/(1.73 m^2)) CKD-Epi (mL/min) Pharmacokinetics k hr^-1 Half-Life hr Low Vd L High Vd L Dosing Interval hr Mainenance Dose mg Double Check MD mg Tau hr Cmax mg/L Cpk mg/L Cmin mg/L",
    "tags": "",
    "url": "/peripheral_brain/calculators/aminoglycosideInitial.html"
  },{
    "title": "Aminoglycoside Peak-Trough Dosing Calculator",
    "text": "Current Patient Values Dose (mg) Pt Peak (mg/L) Pt Trough (mg/L) Current Dosing Interval (hr) Current Infusion Time (hr) Max-Peak Interval (hr) Trough-Min Interval (hr) Desired Values Desired Peak (mg/L) Desired Trough (mg/L) Infusion Time (hr) Max-Peak Interval (hr) Dosing Interval (hr) MD (mg) Pharmacokinetics k hr^-1 Half-Life hr Pt Vd L Dosing Interval hr Mainenance Dose mg Double Check MD mg Tau hr Cmax mg/L Cpk mg/L Cmin mg/L Next Dose Delay* Delay hr *This value represents the minimum time elapsed between the last peak and the next administration to garuntee the drug has decreased below the desired trough concentration",
    "tags": "",
    "url": "/peripheral_brain/calculators/aminoglycosidePeakTrough.html"
  },{
    "title": "Common Patient Calculations",
    "text": "Height (in) Weight (kg) Age (yrs) SCr (mg/dL) Sex Male Female Race African American Other Weights IBW kg ABW kg LBW kg BSA m^2 Kidney Function CG-CrCl mL/min Weight Used for CG CKD-Epi (mL/min/(1.73 m^2)) CKD-Epi (mL/min)",
    "tags": "",
    "url": "/peripheral_brain/calculators/commonCalcs.html"
  },{
    "title": "Vancomycin Initial Dosing",
    "text": "Height (in) Weight (kg) Age (yrs) SCr (mg/dL) Sex Male Female Race African American Other CrCl (mL/min) CKD-Epi CG-CrCl Other: MIC (mg/L) Low Vd (L/kg) High Vd (L/kg) Volume (L) Desired Peak (mg/L) Desired Trough (mg/L) Infusion Time (hr) Max-Peak Interval (hr) Dosing Interval (hr) MD (mg) Kidney Function CG-CrCl mL/min Weight Used for CG CKD-Epi (mL/min/(1.73 m^2)) CKD-Epi (mL/min) Pharmacokinetics k hr^-1 Half-Life hr Low Vd L High Vd L Dosing Interval hr Mainenance Dose mg Double Check MD mg Tau hr Cmax mg/L Cpk mg/L Cmin mg/L AUC0-24hr mg*hr/L AUC0-24hr / MIC Note: Maximum Infusion Rate of 15mg/min",
    "tags": "",
    "url": "/peripheral_brain/calculators/vancInitial.html"
  },{
    "title": "Vancomycin Peak-Trough Dosing",
    "text": "Current Patient Values Dose (mg) Pt Peak (mg/L) Pt Trough (mg/L) Current Dosing Interval (hr) Current Infusion Time (hr) Max-Peak Interval (hr) Trough-Min Interval (hr) MIC (mg/L) Desired Values Desired Peak (mg/L) Desired Trough (mg/L) Infusion Time (hr) Max-Peak Interval (hr) Dosing Interval (hr) MD (mg) Pharmacokinetics k hr^-1 Half-Life hr Pt Vd L Dosing Interval hr Mainenance Dose mg Double Check MD mg Tau hr Cmax mg/L Cpk mg/L Cmin mg/L AUC0-24hr mg*hr/L AUC0-24hr / MIC Note: Maximum Infusion Rate of 15mg/min",
    "tags": "",
    "url": "/peripheral_brain/calculators/vancPeakTrough.html"
  },{
    "title": "The 1st 5 Minutes",
    "text": "ACS MONA Morphine 2-4mg IV q5-30min in increments of 2-8mg PRN BP and RR after each bolus Can consider meperidine or other opiod D/C all NSAIDs and avoid all NSAIDs during admission O2 to sat of 95% if &lt; 90% on presentation SL NTG 0.4mg q5min x3, if non-responsive start IV NTG 5-10mcg/min to 75-100mcg/min (Max 200, consider 1-2min bolus of 400mcg/min to load) Verify NO PDEIs w/i 24-36hr IV Contraindicated w/ SBP &lt; 90; &gt; 30 mmHg change from baseline; Bradycardia or Tachycardia; Suspected RV Infarction Monitor BP and HR q2h while on IV ASA 325mg Chewed and Swallowed on presentation Consider anxiolytics to decrease HR and demand Consider PCI for STEMI Consult ACS for further management Stroke Labs Conduct NIHSS (National Institutes of Health Stroke Scale) Head CT to r/o hemorrhagic stroke Monitor BP / O2Sat BG BMP CBC INR / aPTT EKG Echo Pt is NPO until swallow study conducted Initial Therapies Manage BG if abnormal Hypoglycemia can result in stroke SSx Hyperglycemia above 180 mg/dL can result in higher morbidity / mortality Consider thrombolytics for ischemic strokes (must r/o hemorrhagic) Manage HTN to &lt; 220/120 for non-thrombolytic pts, &lt; 180/105 for thrombolysis IV antihypertensives warranted, do not lower BP excessively, as elevated BP may help perfuse partially occluded areas Agressive BP control can limit stroke recurrence, long-term neuro deficits, an decrease risk of cerebral edema; however concern from above usually wins, attempt to balance (i.e 150s instead of 170s or 110s) Thrombolysis Dosing Must satisfy inclusion / exclusion criteria below 0.9 mg/kg NTE 90mg Total dose 10% (0.09 mg/kg) IVPB over 1min 90% (0.81 mg/kg) IV over 60min Give w/i 60min of arrival Keep BP &lt; 180/105 Monitor q15min x2h then q30min x 6h then q1h x16hr Can begin to lower to outpt goal after 24h Avoid all antiplatelets and anticoagulants for 24hr post-admin SEs Bleeding Stroke Conversion Cerebral Edema Inclusion Criteria Ischemic stroke confirmed by imaging &lt; 3hrs from SSx onset Extended interval available, see below Some evidence for imaging-based determination of thrombolysis eligbility here, but not currently in guidelines ≥ 18yo Exclusion Criteria Evidence of active internal bleed Hx of intracranial hemorrhage Previous stroke or head trauma in less than 3mo GI or GU hemorrhage in ≤ 21d Major surgery in ≤ 14d MI in ≤ 3mo BP &gt; 185/110 at administration time BG &lt; 50 mg/dL Plt &lt; 100k Current anticoag w/ INR &gt; 1.7 or aPTT &gt; 45s NOACs CI tPA Reversible exclusion criteria Extended tPA Window &lt; 4.5hrs after SSx onset Add the following to the exclusion criteria Age ≥ 80 Hx of Stroke w/ DM Any recent anticoag use NIHSS &gt; 25 BP Control Use common IV antihypertensives discussed in HTN Crisis section Labetalol 10-20mg IVPB q10-20min NTE 300mg Nicardipine 5mg/hr IV titrated q5min NTE 15 mg/hr Nitroprusside 0.5-10 mcg/kg/min titrated (preferable if DBP &gt; 140) Transfusion for Severe Acute Anemia Criteria Acutely Symptomatic Hgb &lt; 8 (some argue 7) Admin PRBCs Type and cross before admin 1 U &amp;approx; 300 mL &amp;approx; Δ 1 g/dL Hgb Consider activation of massive transfusion protocol Hemorrhaging / trauma pts may require infusions of FFP and Plt as well to sustain coagulation, strongly consider before using large volumes of crystalloid Pts refusing transfusion can be given high dose iron, B12, and Epo, look up protocol Complications Iron Overload Infection (HIV etc, rare) Hyperviscosity syndrome Alloimmunization Volume overload Transfusion reactions",
    "tags": "",
    "url": "/peripheral_brain/firstFive"
  },{
    "title": "Formulas",
    "text": "Dosing and Body Weights Acid-Base Nitrogen Balance Fluids and Electrolytes Anticoagulation EKG Interpretation Pharmacokinetics General PK 1-Compartment Model",
    "tags": "",
    "url": "/peripheral_brain/formulas"
  },{
    "title": "Lab Values",
    "text": "ABG pH / paCO2 / paO2 / [HCO3]- / O2 Sat Lab Low High Units pH 7.35 7.45 n/a paCO2 35 45 mmHg paO2 80 100 mmHg HCO3- 22 26 mEq/L O2 Sat 95% 100% % Saturation Electrolytes Lab Low High Units pH 7.35 7.45 n/a Na+ 135 145 mEq/L Cl- 95 105 mEq/L K+ 3.5 5 mEq/L Ca2+ 8.5 10.5 mg/dL Ionized Ca2+ 4.6 5.1 mg/dL HCO3- 22 26 mEq/L Mg2+ 1.5 2.5 mg/dL PO43- 2.5 4.5 mg/dL Osm 275 290 mOsm/L Anion Gap 3 11 mEq/L Chem7 Na K Cl Bicarb BUN SCr Gluc Hematology WBC Plt Hgb Hct Lab Low High Unit Hgb (M) 13.5 17.5 g/dL Hgb (F) 12 16 g/dL Hct (M) 41 53 % Hct (F) 36 46 % RBC (M) 4.5 5.9 M/mcL RBC (F) 4.1 5.1 M/mcL MCV 80 100 fL RDW 11 15 % Folate 1.8 16 ng/mL B12 100 900 pg/mL Cells Low % High % Segmented 45 75 Bands 3 5 Lymphocytes 20 40 Monocytes 2 8 Eosinophils 0 4 Basophils 2 2 Lab Low High Unit Ferritin 10 20 mcg/L Serum Iron 60 150 mcg/dL Transferrin 20 50 % TIBC 250 400 mcg/dL Anticoagulation Monitoring Test Evaluating Low High Units Platelet Count Bone Marrow 150 450 k/mm3 PT Extrinsic Pathway 12 14 sec INR Extrinsic Pathway - 1.1 n/a aPTT Intrinsic Pathway 26 33 sec EKG Normal Values Measure Interval (ms) PR Interval 120-200 QRS 80-120 QT* 380-460 QTc (Male)* 360-470 QTc (Female)* 360-480 *High risk of Torsades w/ QTc ≥500ms",
    "tags": "",
    "url": "/peripheral_brain/lab_values"
  },{
    "title": "Sources",
    "text": "Cardiology ACS AHA NSTE-ACS Guidelines 2014 [^amsterdam2014]: Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017 AHA STEMI Guidelines [^ogara2013]: O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. *Journal of the American College of Cardiology*. 2013;61(4):e78-e140. doi:[10.1016/j.jacc.2012.11.019](https://doi.org/10.1016/j.jacc.2012.11.019) Benign Early Repol vs Subtle LAD STEMI (4-variable) [^driver2017]: Driver BE, Khalil A, Henry T, Kazmi F, Adil A, Smith SW. A new 4-variable formula to differentiate normal variant ST segment elevation in V2-V4 (early repolarization) from subtle left anterior descending coronary occlusion - Adding QRS amplitude of V2 improves the model. *Journal of Electrocardiology*. 2017;50(5):561-569. doi:[10.1016/j.jelectrocard.2017.04.005](https://doi.org/10.1016/j.jelectrocard.2017.04.005) DAPT Duration in CAD [^levine2016]: Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. *Journal of the American College of Cardiology*. 2016;68(10):1082-1115. doi:[10.1016/j.jacc.2016.03.513](https://doi.org/10.1016/j.jacc.2016.03.513) LBBB vs STEMI [^smith2012]: Smith SW, Dodd KW, Henry TD, Dvorak DM, Pearce LA. Diagnosis of ST-Elevation Myocardial Infarction in the Presence of Left Bundle Branch Block With the ST-Elevation to S-Wave Ratio in a Modified Sgarbossa Rule. *Annals of Emergency Medicine*. 2012;60(6):766-776. doi:[10.1016/j.annemergmed.2012.07.119](https://doi.org/10.1016/j.annemergmed.2012.07.119) Third Universal MI Definition [^thygesen]: Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third Universal Definition of Myocardial Infarction. :16. STEMI PCI Update [^levine2015]: Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction. *Journal of the American College of Cardiology*. 2016;67(10):1235-1250. doi:[10.1016/j.jacc.2015.10.005](https://doi.org/10.1016/j.jacc.2015.10.005) HTN AHA HTN Guidelines [^whelton2018]: Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. *Journal of the American College of Cardiology*. 2018;71(19):e127-e248. doi:[10.1016/j.jacc.2017.11.006](https://doi.org/10.1016/j.jacc.2017.11.006) VTE VTE Treatment Guidelines [^kearon2016]: Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease. Chest. 2016;149(2):315-352. doi:[10.1016/j.chest.2015.11.026](https://doi.org/10.1016/j.chest.2015.11.026) VTE Prophylaxis [^gould2012]: Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in Nonorthopedic Surgical Patients. Chest. 2012;141(2):e227S-e277S. doi:[10.1378/chest.11-2297](https://doi.org/10.1378/chest.11-2297) CHF [^yancy2013]: Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;128(16). doi:[10.1161/CIR.0b013e31829e8776](https://doi.org/10.1161/CIR.0b013e31829e8776) [^yancy2017]: Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. *Journal of the American College of Cardiology*. 2017;70(6):776-803. doi:[10.1016/j.jacc.2017.04.025 Critical Care Hypotension Management Push-Dose Pressors [^weingart2015]: Weingart S. Push-dose pressors for immediate blood pressure control. *Clinical and Experimental Emergency Medicine*. 2015;2(2):131-132. doi:[10.15441/ceem.15.010](https://doi.org/10.15441/ceem.15.010) [^hollenberg2011]: Hollenberg SM. Vasoactive Drugs in Circulatory Shock. American Journal of Respiratory and Critical Care Medicine. 2011;183(7):847-855. doi:[10.1164/rccm.201006-0972CI](https://doi.org/10.1164/rccm.201006-0972CI) [^jentzer2015]: Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. Journal of Cardiovascular Pharmacology and Therapeutics. 2015;20(3):249-260. doi:[10.1177/1074248414559838](https://doi.org/10.1177/1074248414559838) [^overgaard2008]: Overgaard CB, Džavík V. Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease. Circulation. 2008;118(10):1047-1056. doi:[10.1161/CIRCULATIONAHA.107.728840](https://doi.org/10.1161/CIRCULATIONAHA.107.728840) ID Vancomycin Dosing Optimizing Vancomycin Dosing [^deryke2009]: Deryke CA, Alexander DP. Optimizing Vancomycin Dosing through Pharmacodynamic Assessment Targeting Area under the Concentration-Time Curve/Minimum Inhibitory Concentration. *Hospital Pharmacy*. 2009;44(9):751-765. doi:[10.1310/hpj4409-751](https://doi.org/10.1310/hpj4409-751) Vancomycin PK in Renal Dysfunction [^matzkel1984]: Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. *Antimicrobial Agents and Chemotherapy*. 1984;25(4):433-437. doi:[10.1128/AAC.25.4.433](https://doi.org/10.1128/AAC.25.4.433) ASHP Vancomycin Monitoring Recommendations [^rybak2009]: Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *American Journal of Health-System Pharmacy*. 2009;66(1):82-98. doi:[10.2146/ajhp080434](https://doi.org/10.2146/ajhp080434) Aminoglycoside Dosing Stanford Health System Aminoglycoside Dosing Recommendations [^mui2017]: Mui, E. Stanford Health Care Aminoglycoside Dosing Guideline. 2017. [Link](http://med.stanford.edu/bugsanddrugs/dosing-protocols/_jcr_content/main/panel_builder/panel_0/download_2/file.res/Aminoglycoside%20Dosing%20Guide%202017-08-23.pdf) Extended Interval Aminoglycosides [^nicolau1995]: Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. *Antimicrobial Agents and Chemotherapy*. 1995;39(3):650-655. doi:[10.1128/AAC.39.3.650](https://doi.org/10.1128/AAC.39.3.650) Textbooks Pharmacology DiPiro Pharmacotherapy [^dipiro]: DiPiro JT, ed. *Pharmacotherapy: A Pathophysiologic Approach*. Tenth edition. New York: McGraw-Hill Education; 2017. Emergency Medicine Tintinalli’s [^tintinalli]: Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM, eds. *Tintinalli’s Emergency Medicine: A Comprehensive Study Guide*. Eight edition. New York: McGraw-Hill Education; 2016. Websites Drug Resources Lexicomp [^lexi]: Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: [http://online.lexi.com](http://online.lexi.com).",
    "tags": "",
    "url": "/peripheral_brain/sources"
  },{
    "title": "ACS",
    "text": "Dx 1,2 ECG w/i 10min of arrival, then Q15-30min x1hr if not initially diagnositc CXR / Chest CT to r/o thoracic aortic aneurysm / dissection, PE, pneumothorax, PNA, etc Serial cTn ASAP then Q3-6hr TIMI Risk Score for all NSTE-ACS (1pt for each below 3) ≥ 65yo Prior Coronary Stenosis ≥ 50% ST Depression ≥ 0.5mm ≥ 2 Anginal events w/i 24hrs ASA use w/i 7d (+) Cardiac Enzymes ≥ 3 CAD risk factors Smoking HTN Dyslipidemia DM FHx of premature CAD or Sudden Cardiac Death GRACE Risk Score STEMI Dx Criteria ESC/ACC/AHA 4,5 ST Elevation in 2 anatomically contiguous leads ≥ 0.1mV at the J-point except V2-V3 (use the following in V2-V3 Men ≥ 40: ≥ 0.2 mV Men &lt; 40: ≥ 0.25 mV Women: ≥ 0.15 mV New horizontal / down-sloping ST-depression in 2 contiguous leads ≥ 0.05 mV T-wave Inversion in 2 contiguous leads ≥ 0.1 mV with prominent R waves or Definitively new LBBB In the presence of existing LBBB consider Smith-Modified Sgarbossa Criteria 6 ≥ 3 points ⇒ 98% Likelihood of MI ST-elevation ≥1 mm in a lead with upward QRS complex (concordant) - 5 points ST-depression ≥1 mm in lead V1, V2, or V3 - 3 points - 2 points New LAFB and RBBB is concerning for LAD occlusion ST-elevation with ST-depression in aVL is highly suspicious for STEMI Local ST-depression in V1-V4 is suspicious for isolated posterior infarct ST-elevation in aVL with depression in III is suspicious for high lateral MI Subtle LAD occlusion vs EBR 7 0.052 x QTc - 0.151 x (QRS voltage in V2) - 0.268 x (R-wave amplitude in V4) + 1.062 x (ST-elevation 60ms after J-point in V3) ≥ 18.2 ⇒ 88.8% sensitive, 94.7% specific ≥ 17.75 ⇒ 90.2% sensitive, 90.6% specific Infarction EKG Patterns 1 Location Electrocardiographic Findings Artery Anteroseptal ST-segment elevations in V1, V2, and possibly, V3 LAD Anterior ST-segment elevations in V1, V2, V3, and V4 LAD Anterolateral ST-segment elevations in V1–V6, I, and aVL LAD or LCX Lateral ST-segment elevations in I and aVL LCX Inferior ST-segment elevations in II, III, and aVF RCA or RCX (20%) Inferolateral ST-segment elevations in II, III, aVF, and V5 and V6 LCX or RCA or RCX True posterior Initial R waves in V1 and V2 &gt; 0.04 s and R/S ratio ≥ 1 LCX Right ventricular ST-segment elevations in II, III, and aVF and ST elevation in right-side V4 RCA Tx 1,4 Empiric ASA 325mg (chew &amp; swallow) for all pts at risk for AMI w/o CIs Nitrates Nitro 0.4mg SL Q5min x3 doses Nitro IV Start at 10 mcg/min, titrate to 10% reduction in MAP if normotensive, 30% reduction in MAP if hypertensive Avoid in RV infarction (d/t dependance on preload for maintaining CO) CI w/ PDE-5 Inhibitors w/i 24hr (48hr if Tadalafil) Supplemental O2 PRN for O2Sat &lt; 90% Morphine 2-5mg IV Q5-15min PRN is the preferred method of pain control d/t vasodilatory properties STEMI 1,4 PCI Management PCI w/i 90min if PCI at facility or w/i 120min for transfer if... &lt;12hr from SSx onset &lt;12h and CI to fibrinolytics regardless of time limits above Cardiogenic shock or acute HF regardless of SSx onset Potentially if SSx for 12-24hr P2Y12 Inhibitor Clopidogrel 600mg load then 75mg PO QD x1yr Prasugrel 60mg load then 10mg PO QD x1yr (CI w/ prior stroke) Ticagrelor 180mg load then 90mg PO BID x1yr (ASA NTE 100mg w/ ticagrelor) Anticoag UFH w/ GP IIb/IIIa: 50-70 U/kg bolus targeting aPTT 200-250s UFH w/o GP IIB/IIIA: 70-100 U/kg bolus targeting aPTT 250-350s Bivalirudin 0.75 mg/kg bolus then 1.75 mg/kg/hr Reduce to 1 mg/kg/hr if CrCl &lt; 30 Preferred over UFH w/ GP IIb/IIIa if high bleed risk GP IIb/IIIa Inhibitors Only for select patients Abciximab 0.25 mg/kg IVB then 0.125 mcg/kg/min NTE 10 mcg/min Tirofiban 25 mcg/kg IVB then 0.15 mcg/kg/min CrCl &lt; 30: Reduce rate by 50% Eptifibatide 180 mcg/kg IVB then 2 mcg/kg/min then 180 mcg/kg IVB 10min after 1st IVB CrCl &lt; 50: Reduce rate by 50% Avoid in pts on HD Medical Management Thrombolytics preferably w/i 30min, should be w/i 1-2hr of presentation if PCI not indicated from above (see dosing below) SSx &lt; 12h Potentially if SSx for 12-24hr Check All CIs to thrombolytics closely Clopidogrel ≤ 75yo: 300mg load then 75mg QD x14d-1yr &gt; 75yo: 75mg QD x14d-1yr (no load) Anticoag UFH Target aPTT 1.5-2x ULN (⇒ 50-70s) x48hr or until revascularization 60 U/kg IVB NTE 4000 U then 12 U/kg/hr NTE 1000 U/hr initially titrated to above goal Enoxaparin &lt; 75yo: 30mg IV then 15min later 1 mg/kg SubQ Q12H NTE 100mg for the 1st 2 doses ≥ 75yo: 0.75 mg/kg SubQ Q12H NTE 75mg for the 1st 2 doses CrCl &lt; 30: 1 mg/kg Q24H instead For duration of stay NTE 8d or until revascularization (unless other indication arises) Fondaparinux 2.5mg IVB then 2.5mg SubQ QD starting the next day CI if CrCl &lt; 30 For duration of stay NTE 8d or until revascularization (unless other indication arises) NSTE-ACS 2 Choosing Strategies Early Invasive w/i 2hr Refractory Angina Hemodynamic / Electrical Instability Sustained VT / VF SSx of HF or mitral regurgitation Stable pts w/ increased risk of clinical events Early-invasive (&lt; 24hr) is better than delayed-invasive if intermediate-high risk Ischemia Guided Extensive co-morbidities significantly increasing the risk of catheterization Acute chest-pain that has a low likelihood of being ACS who are (-) troponin, esp. in women TIMI 0-1 or Grace &lt; 109 Pt / clinician preference in pts w/o high-risk features Early Invasive w/i 24hr None of above but GRACE &gt; 140 Changes in Troponin New ST depression Delayed Invasive (25-72hr) None of above but DM CrCl &lt; 60 LVEF &lt; 40% PCI w/i 6mo Prior CABG GRACE 109-140 or TIMI ≥ 2 Early postinfarction angina Ischemia Guided Strategy P2Y12 Inhibitor Clopidogrel 600mg load then 75mg PO QD x1yr Ticagrelor 180mg load then 90mg PO BID x1yr (ASA NTE 100mg w/ ticagrelor, preferred) Anticoag UFH 60 U/kg load NTE 4000 U then 12 U/kg/h NTE 1000 U/hr titrated to therapeutic aPTT x48hr or until PCI Enoxaparin 30mg mg/kg IV loading dose then 1 mg/kg Q12H w/ typical renal adjustments for duration of stay or until PCI Fondaparinux 2.5mg SubQ QD for duration of stay or until PCI Early-Invasive Strategy P2Y12 Inhibitor Clopidogrel 600mg load then 75mg PO QD x1yr Ticagrelor 180mg load then 90mg PO BID x1yr (ASA NTE 100mg w/ ticagrelor, preferred) Anticoag UFH 60 U/kg load NTE 4000 U then 12 U/kg/h NTE 1000 U/hr titrated to therapeutic aPTT x48hr or until PCI Bivalirudin 0.1 mg/kg bolus then 0.25 mg/kg/hr Enoxaparin 30mg mg/kg IV loading dose then 1 mg/kg Q12H w/ typical renal adjustments for duration of stay or until PCI Fondaparinux 2.5mg SubQ QD for duration of stay or until PCI GP IIb/IIIa Inhibitors (high-risk only) Only for select patients Tirofiban 12 mcg/kg IVB then 0.14 mcg/kg/min CrCl &lt; 30: Reduce rate and bolus by 50% Eptifibatide 180 mcg/kg IVB then 2 mcg/kg/min CrCl &lt; 50: Reduce rate by 50% Avoid in pts on HD Thrombolytic Dosing 8 tPA 15mg IVB over 1-2min then 0.75mg/kg IV over 30min NTE 50mg then 0.5 mg/kg IV over 1hr NTE 35mg Total dose NTE 100mg Wt to achieve max dose: 67kg Reteplase 10 Units IV over 2min then 10 Units IV over 2min 30min later Tenecteplase IV bolus over 5 seconds &lt;60 kg: 30 mg ≥ 60 to &lt;70 kg: 35 mg ≥ 70 to &lt;80 kg: 40 mg ≥ 80 to &lt;90 kg: 45 mg ≥ 90 kg: 50 mg Thrombolytic CIs 4 Absolute CIs Any prior ICH Known structural cerebral vascular lesion (e.g., arteriovenous malformation) Known malignant intracranial neoplasm (primary or metastatic) Ischemic stroke within 3 mo EXCEPT acute ischemic stroke within 4.5 h Suspected aortic dissection Active bleeding or bleeding diathesis (excluding menses) Significant closed-head or facial trauma within 3 mo Intracranial or intraspinal surgery within 2 mo Severe uncontrolled hypertension (unresponsive to emergency therapy) For streptokinase, prior treatment within the previous 6 mo Relative CIs History of chronic, severe, poorly controlled hypertension Significant hypertension on presentation (SBP &gt; 􏰁180 mm Hg or DBP &gt; 􏰁110 mm Hg) History of prior ischemic stroke &gt; 􏰁3 mo Dementia Known intracranial pathology not covered in absolute contraindications Traumatic or prolonged ( &gt; 􏰁10 min) CPR Major surgery ( &lt; 􏰂3 wk) Recent (within 2 to 4 wk) internal bleeding Noncompressible vascular punctures Pregnancy Active peptic ulcer Oral anticoagulant therapy Post-ACS Chronic Therapies Beta-blockers in pts w/o CIs ACEIs / ARBs, esp in pts w/ LVEF &lt; 40% High-Intensity Statins NTG SL PRN References Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM, eds. Tintinalli’s Emergency Medicine: A Comprehensive Study Guide. Eight edition. New York: McGraw-Hill Education; 2016. &#8617; &#8617;2 &#8617;3 &#8617;4 Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017 &#8617; &#8617;2 DiPiro, JT, ed. Pharmacotherapy: A Pathophysiologic Approach. Tenth edition. New York: McGraw-Hill Education, 2017. &#8617; O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology. 2013;61(4):e78-e140. doi:10.1016/j.jacc.2012.11.019 &#8617; &#8617;2 &#8617;3 &#8617;4 Thygesen, K, Alpert, JS, Jaffe, AS, Simoons, ML, Chaitman, BR, and White, HD. Third Universal Definition of Myocardial Infarction.16. &#8617; Smith, SW, Dodd, KW, Henry, TD, Dvorak, DM, and Pearce, LA. Diagnosis of ST-Elevation Myocardial Infarction in the Presence of Left Bundle Branch Block With the ST-Elevation to S-Wave Ratio in a Modified Sgarbossa Rule. Annals of Emergency Medicine 2012;60:766–776. &#8617; Driver, BE, Khalil, A, Henry, T, Kazmi, F, Adil, A, and Smith, SW. A New 4-Variable Formula to Differ- entiate Normal Variant ST Segment Elevation in V2-V4 (Early Repolarization) from Subtle Left Anterior Descending Coronary Occlusion - Adding QRS Amplitude of V2 Improves the Model. Journal of Electrocardiology 2017;50:561–569. &#8617; Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. &#8617;",
    "tags": "",
    "url": "/peripheral_brain/diseases/acs.html"
  },{
    "title": "APAP Overdose",
    "text": "Dx1 APAP toxicity usually seen with ingestions of &gt;10g or 200mg/kg in 24hr OR &gt;6g or 150mg/kg QD x2d SSx N/V Anorexia Abd pain HypoK Abnormal LFTs Encephalopathy Jaundice Anuria Workup Serum APAP &gt;4hr post-ingestion for nomogram below Others as indicated Serum ASA Chem7 CBC LFTs SCr / BUN Urine Tox Tx1,2 Use Rumack-Matthew Nomogram if level not available w/i 8hr, treat empirically Activated Charcoal 1g/kg if recent exposure, preferably w/i 1hr, but maybe 3-4hr post-exposure NAC as dosed below if above nomogram line or if &gt;24hr post-exposure w/ level &gt;10 mcg/mL (mg/L) Dosing wt NTE 100kg 100mg/kg IV over 15-60min then 50mg/kg IV over 4hr then 100mg/kg IV over 16hr all in D5W PO therapy also available watch for tinnitus and anaphylaxis Admit consider transplant if AMS, PTT &gt;100, pH &lt; 7.3, or SCr &gt; 3.3 after delayed therapy (&gt;24hr post-exposure) APAP Nomogram1 References Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM, eds. Tintinalli’s Emergency Medicine: A Comprehensive Study Guide. Eight edition. New York: McGraw-Hill Education; 2016. &#8617; &#8617;2 &#8617;3 Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. &#8617;",
    "tags": "",
    "url": "/peripheral_brain/diseases/apapOverdose.html"
  },{
    "title": "CHF",
    "text": "Dx1 HFrEF: HF w/ LVEF ≤ 40% HFpEF: HF w/ LVEF ≥ 50% &gt; 40% is borderline HFpEF Measure NT-proBNP or BNP if suspicious CXR and Doppler Echo on initial workup Staging / Classification AHA Stages Stage Description A High risk w/o structural heart disease and w/o HF SSx B SHD w/o SSx of HF C SHD w/ current or prior HF SSx D Refractory HF SSx NYHA Classifications Classification Description I No limitations of physical activity d/t SSx II Normal physical activity results in SSx III Mild physical activity results in SSx IV SSx at rest DDx of Dilated Cardiomyopathies Genetic / Familial Obesity DM Hyperthyroidism Acromegaly EtOH Cocaine HER-2 and/or anthracyclines Various other toxins Chronic Tachycardia Myocarditis SLE HIV Other infections Chagas disease Hypersensitivity myocarditis Scleroderma and other rheumatologist conditions Peripartum cardiomyopathy Hemochromatosis and iron overload Amyloidosis Tx (HFrEF)1, 2 Stage A Modify risk factors as appropriate, with emphasis on wt loss, smoking cessation, BP control, HLD control, and DM control Stage B All pts should receive… ACEI (ARB if CI) β-blocker Metoprolol tartrate Bisoprolol Carvedilol Statins (if Hx of ACS or CAD) Other means of BP control PRN Consider spironolactone if HTN is refractory to above agents Consider prophylactic ICD Stage C All pts should receive… ACEI or ARB or ARNI Tolerating ACEI or ARB and able to afford =&gt; transition to ARNI Do not give ARNI w/i 36hr of ACEI or ARB Do not give ARNIs to pts w/ Hx of angioedema Monitor and titrate slowly Q1-2wks β-blocker Metoprolol tartrate Bisoprolol Carvedilol Consider ivabridine if on maximum BB dose, LVEF ≤ 35%, and RHR ≥ 70 Start low and titrate up when SSx of current dose abide Spironolactone CrCl &gt; 30 and K &lt; 5 If LVEF ≤ 35% OR LVEF ≤ 40% w/ HF or DM after MI Consider Hydralazine-Nitrate combos in black pts PRN Diurectics for fluid status control Preferably Loops, with thiazides added for diuretic resistance PRN Additional BP Meds PRN for goal of &lt; 130/80 Consider Digoxin to decrease hospitalizations 0.125-0.25mg QD NTE 0.5-0.75mg QD Goal Plasma Range of 0.5-0.9 ng/mL Avoid CCBs except amlodipine Dosing HF Drug Dosing Drug Initial Dose Max Dose ACEIs Captopril 6.25mg TID 50mg TID Enalapril 2.5mg BID 10-20mg BID Lisinopril 2.5-5mg QD 20-40mg QD ARBs Candesartan 4-8mg QD 32mg QD Losartan 25-50mg QD 50-150mg QD Valsartan 20-40mg BID 160mg BID ARNI Sacubitril/Valsartan 49mg/51mg BID(or 24mg/26mg BID) 97mg/103mg BID If Channel Inhibitor Ivabradine 5mg BID 7.5mg BID Aldosterone Antagonists Spironolactone 12.5-25mg QD 25mg QD or BID Eplerenone 25mg QD 50mg QD β-Blockers Bisoprolol 1.25mg QD 10mg QD Carvedilol 3.125mg BID 50mg BID Carvedilol CR 10mg QD 80mg QD Metoprolol Succinate 12.5-25mg QD 200mg QD ISDN-Hydralazine Combo Pill 20mg/37.5mg TID 40mg/75mg TID Individual Pills 20-30mg/25-50mg TID or QD 40mg TID / 100mg TID HF Diuretic Dosing Drug Initial Dose Max TDD Loops Bumetanide 0.5-1mg QD-BID 10mg Furosemide 20-40mg QD-BID 600mg Torsemide 10-20mg QD 200mg Thiazides Chlorthiazide 250-500mg QD-BID 1000mg Chlorthalidone 12.5-25mg QD 100mg HCTZ 25mg QD or BID 200mg Indapamide 2.5mg QD 5mg Metolazone 2.5mg QD 20mg K-Sparing Amiloride 5mg QD 20mg Spironolactone 12.5-25 QD 50mg Triamterene 50-75mg BID 200mg Stage D Fluid restrict to 1.5-2 L QD Consider milrinone or dobutamine for inotropy Consider LVAD Consider transplant Acute Decompensated HF1, 3 Continue home HF meds unless CI or hemodynamically unstable / failing renal Fx IV diuretics for fluid-overloaded pts Furosemide 40mg, Bumetanide 1-3mg, or Torsemide 10-20mg for naive pts Should give higher doses than home Give vasodilators if pt has adequate hemodynamics and significant dyspnea NTG 0.5-0.7 mcg/kg/min IV titrated NTE 200 mcg/min Nitroprusside 0.3 mcg/kg/min titrated q5-10min Nesiritide 2mcg/kg then 0.01 mcg/kg/min4 Pressors / Inotropes if not perfusing Milrinone 50 mcg/kg over 10min then 0.5 mcg/kg/min Dobutamine 2-20 mcg/kg/min Consider LVAD or ECMO if absolutely necessary References Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16). doi:10.1161/CIR.0b013e31829e8776 &#8617; &#8617;2 &#8617;3 Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology. 2017;70(6):776-803. doi:[10.1016/j.jacc.2017.04.025 &#8617; Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM, eds. Tintinalli’s Emergency Medicine: A Comprehensive Study Guide. Eight edition. New York: McGraw-Hill Education; 2016. &#8617; Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. &#8617;",
    "tags": "",
    "url": "/peripheral_brain/diseases/chf.html"
  },{
    "title": "VTE",
    "text": "Dx DVT: Well’s Score PE: PERC Rule DVT Prophylaxis1 Low Risk: Consider ICD or no therapy High bleeding risk: ICD over no therapy Otherwise: LMWH or UFH (low dose) Parenteral Dosing2 Drug Dose Adjustments Notes UFH 5000 Units Q8-12H None Higher risk of HIT Enoxaparin 40mg SubQ QD30mg SubQ BID CrCl &lt; 30: 30mg SubQ QD Low risk of HIT Fondaparinux 2.5mg SubQ QD CrCl 30-50: CautionCrCl &lt; 30: CI Must be ≥ 50kg PO Dosing2 Drug Indication Dosing Adjustments Notes Rivaroxiban THA or TKA 10mg QD x10-14d NTE 34d starting 6-10hr after surgery CrCl 30-50: CautionCrCl &lt; 30: CI Use longer interval for THA, shorter end for TKA Apixaban THA or TKA 2.5mg BID x10-14d NTE 34d starting 12-24hr after surgery CrCl &lt; 30: No evidence   Dabigatran THA 110mg x1 dose 1-4hr after surgery OR 220mg on the first day, then 220mg QD 10-14d NTE 35d CrCl 30-50: Consider 150mg QD instead of 220mgCrCl &lt; 30: No evidence Times close to 30d recommendedWatch w/ PGP inhibitors DVT Tx3 At least 3mo anticoag PO therapy (DOAC or warfarin) preferred if no cancer LMWH preferred if cancer Generally stick to 3, low-moderate bleed risk unprovoked VTE recommend extended (no scheduled stop date) If DVT recurs while on anticoag, switch to LMWH or increase LMWH by 25-33% if already on LMWH ASA is not as good as anticoag, but better than nothing Distal DVT w/ serial imaging can forgo anticoag if thrombus does not extend PE Tx3 Low Risk: Tx outpatient Thrombolysis for hemodynamic instability (SBP &lt; 90) w/o high bleed risk Give thrombolytics if pt deteriorates after anticoag if low bleed risk Systemic over catheter directed Can be used in stable PE when risks outweigh benefits, but off label and not usually recommended Hemodynamically unstable / shock, high bleed risk, or failure of systemic thrombolysis =&gt; catheter directed removal No thrombolysis if hemodynamically stable DVT/PE Tx Dosing Initial Parenteral Anticoag2 Drug Dose Adjustments UFH 80 U/kg IVB then 18 U/kg/hr333 U/kg SubQ then 250 U/kg Q12H Monitor aPTT Q4-6H (titration) or Q24H (Wt based) based on protocolGoal 1.5-2x ULN Enoxaparin 1 mg/kg SubQ Q12H1.5 mg/kg SubQ Q24H CrCl &lt; 30: 1 mg/kg SubQ Q24H Fondaparinux &lt; 50kg: 5mg SubQ QD50-100kg: 7.5mg SubQ QD&gt; 100kg: 10mg SubQ QDx5-9d CrCl 30-50: CautionCrCl &lt; 30: CI PO Anticoag2 Drug Dose Notes Warfarin 2.5-7.5mg PO QD initial Start w/ parenteral anticoag until therapeutic INRTitrate based on INR (Goal 2-3) Rivaroxaban 15mg PO BID x21d then 20mg PO QD Must be taken w/ foodNo initial parenteral anticoag needed Apixaban 10mg PO BID x7d then 5mg PO QD No initial parenteral anticoag needed Dabigatran 150mg PO BID Initiate after 5d of parenteral anticoagulantAvoid if CrCl ≤ 30 (never in trials)Watch w/ PGP inhibitors Edoxaban &gt; 60kg: 60mg PO QD≤ 60kg: 30mg PO QD Initiate after 5d of parenteral anticoagulantDo not use if CrCl &gt; 95 or &lt; 15CrCl 15-50: 30mg QD Thrombolytics Thrombolytic Dosing2 Drug Dose Notes Alteplase 100mg IV over 2hr Check for CIs (below)Start heparin near end of infusion or when aPTT is 2x ULN Tenecteplase (off-label) Wt based bolus over 5 seconds (See table below) Check for CIs (below) Tenecteplase Dosing2 Wt (kg) Dose &lt; 60kg 30mg [60,70) 35mg [70,80) 40mg [80,90) 45mg ≥ 90 50mg CIs3 Major CIs Structural intracranial disease Previous intracranial hemorrhage Ischemic stroke within 3 mo Active bleeding Recent brain or spinal surgery Recent head trauma with fracture or brain injury Bleeding diathesis Relative CIs Systolic BP &gt;180 Diastolic BP &gt;110 Recent bleeding (non-intracranial) Recent surgery / invasive procedure Ischemic stroke more than 3 mo previously Anticoagulated (eg, VKA therapy) Traumatic CPR Pericarditis or pericardial fluid Diabetic retinopathy Pregnancy Age &gt;75yr Low body weight (eg &lt; 60 kg) Female Black race Preferred Agents Preferred Anticoagulants3 Factor Agent Cancer LMWH Parenteral Therapy CI Rivaroxaban or Apixaban(others require bridge) QD PO Therapy Preferred Rivaroxaban, Edoxaban, Warfarin Liver disease / coagulopathy LMWH CrCl &lt; 30 Warfarin CAD Warfarin, Rivaroxaban, Apixaban, Edoxaban Hx of GI Bleeds Apixaban, Warfarin Thrombolytic Use UFH Infusion Pregnancy LMWH References Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in Nonorthopedic Surgical Patients. Chest. 2012;141(2):e227S-e277S. doi:10.1378/chest.11-2297 &#8617; Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. &#8617; &#8617;2 &#8617;3 &#8617;4 &#8617;5 &#8617;6 Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026 &#8617; &#8617;2 &#8617;3 &#8617;4",
    "tags": "",
    "url": "/peripheral_brain/diseases/vte.html"
  },{
    "title": "Clinical PK",
    "text": "Formulas 1 General PK 1-Compartment Model Vancomycin 1, 2, 3, 4 Peak: 20-40 mg/L Trough: 10-15 mg/L (minor infections) or 15-20 mg/L (serious infections or lung penetration) Loading Dose: 25-30 mg/kg (Wt) NTE 15 mg/min k ≈ 0.00083 × CrCl + 0.0044 Vd ≈ 0.4-1 L/kg, usually 0.6-0.7 L/kg for appropriate effect to prevent toxicity Initial Vanc Dosing Calculator Level-Based Vanc Dosing Calculator Aminoglycosides 1, 5 See also: Stanford Aminoglycoside Dosing Guidelines k ≈ 0.00293 × CrCl + 0.014 Vd ≈ 0.26 L/kg × Wt Vd may be closer to 0.3-0.35 L/kg in critically ill pts due to fluid overload Use ABW if Wt/IBW &gt; 130% Traditional Dosing Gentamicin / Tobramycin Target Levels 1, 6 Infection Target Peak (mcg/mL) Target Trough (mcg/mL) General 4-10 le; 1 UTI &lt; 5 ≤ 1 Bacteremia &gt; 5 ≤ 1 Pneumonia &gt; 6 ≤ 1 Endocarditis from P. aeruginosa &gt; 12 ≤ 1 Amikacin Target Levels 1, 6 Infection Target Peak (mcg/mL) Target Trough (mcg/mL) General 15-30 4-10 UTI &gt; 15 4-10 Bacteremia &gt; 20 4-10 Pneumonia /Serious Infections &gt; 24 4-10 Target Cpk / MIC &gt; 10 for efficacy Draw levels 1hr after infusion ends Consider target troughs of ≤ 1.5-2 (tob/gent) or ≤ 10 (amikacin) for life-threatening infections. Look up specific trough/peak targets for given infection site. Initial Aminoglycoside Dosing Calculator Extended-Interval Dosing Load with 7 mg/kg (15 mg/kg Amikacin) Determine initial dosing frequency from table below Draw level at 6-14hr after 1st or 2nd dose Plot level on Hartford Nomogram (divide level by 2 for Amikacin) If doses other than those above are used, multiplying the level by (expected)/(given) dose can help adjust properly for the nomogram, although this has less evidence Adjust interval per nomogram If borderline, go with longer interval Hartford Nomogram Initial Aminoglycoside Interval CrCl Interval ≥ 60 Q24H 40-59 Q36H 20-39 Q48H &lt; 20 Monitor Serial Conc. &amp; Admin when &lt; 1 mcg/mL References DiPiro JT, ed. Pharmacotherapy: A Pathophysiologic Approach. Tenth edition. New York: McGraw-Hill Education; 2017. &#8617; &#8617;2 &#8617;3 &#8617;4 &#8617;5 Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy. 2009;66(1):82-98. doi:10.2146/ajhp080434 &#8617; Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrobial Agents and Chemotherapy. 1984;25(4):433-437. doi:10.1128/AAC.25.4.433 &#8617; Deryke CA, Alexander DP. Optimizing Vancomycin Dosing through Pharmacodynamic Assessment Targeting Area under the Concentration-Time Curve/Minimum Inhibitory Concentration. Hospital Pharmacy. 2009;44(9):751-765. doi:10.1310/hpj4409-751] &#8617; Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrobial Agents and Chemotherapy. 1995;39(3):650-655. doi:10.1128/AAC.39.3.650 &#8617; Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. &#8617; &#8617;2",
    "tags": "",
    "url": "/peripheral_brain/drugClasses/clinicalPk.html"
  },{
    "title": "Vasopressors",
    "text": "Vasopressors Vasopressor Dosing1 Drug Initial Dose Typical Dose Titration q5-15min Weaning q5-15min Epinephrine 0.02-0.05 mcg/kg/min 0.005-0.2 mcg/kg/min 0.02-0.05 mcg/kg/min 0.02-0.05 mcg/kg/min Norepinephrine 0.01-0.04 mcg/kg/min 0.04-1 mcg/kg/min 0.02-0.04 mcg/kg/min 0.02-0.04 mcg/kg/min Dopamine 5-10 (inotropic)&gt; 10 mcg/kg/min (inopressor) 2-20 mcg/kg/min 2-5 mcg/kg/min 1 mcg/kg/min Phenylephrine 0.1-0.3 mcg/kg/min 0.1-1.5 mcg/kg/min 0.2-0.4 mcg/kg/min 0.2-0.4 mcg/kg/min Vasopressin 0.01-0.04 U/min 0.01-0.04 U/min No titration No weaning Dobutamine 2.5-5 mcg/kg/min 2.5-10 mcg/kg/min 2.5-5 mcg/kg/minAlter based on CO/CI or SVO2 2.5-5 mcg/kg/min Milrinone 0.25 mcg/kg/min 0.25-0.75 mcg/kg/min Alter based on CO/CI or SVO2 No weaning Vasopressor Classification2 Drug Classification Note Epinephrine Inopressor Can bump lactate d/t β stimulation Norepinephrine Inopressor Good 1st line choice in almost all situations Dopamine Inopressor Increased mortality in comparison to NE Phenylephrine Vasopressor   Vasopressin Vasopressor No pulmonary constriction Dobutamine Inodilator Increased myocardial O2 demand d/t chronotropy Milrinone Inodilator Long t1/2 removing need for weaning Vasopressor Hemodynamic Effects2 Drug HR Inotropy Vasoconstriction Vasodilation Dopaminergic Epinephrine ++++ ++++ ++++ +++ 0 Norepinephrine + ++ ++++ 0 0 Dopamine (Inotropy)Dopamine (Inopressor) +++ +++ - +++ 0++ - +++ +0 ++++++ Phenylephrine 0 0 +++ 0 0 Vasopressin 0 0 ++++ 0 0 Dobutamine ++ +++ - ++++ 0 ++ 0 Milrinone + +++ 0 ++ 0 Vasopressor Receptor Specificity3 Drug α-1 β-1 β-2 Other Epinephrine +++++ ++++ +++ - Norepinephrine +++++ +++ ++ - Dopamine +++ ++++ ++ DA Phenylephrine +++++ 0 0 - Vasopressin 0 0 0 V1 (vasoconstriction)V2 (renal tubules) Dobutamine + +++++ +++ - Milrinone 0 0 0 PDE-3 Push-Dose EPI 4 Mixing 9mL NS in 10mL syringe Add 1 mL (100mcg) cardiac epinephrine (0.1mg/mL) Caution: above is for 1mg/10mL (0.1mg/mL) premix syringes, EPI vials are 1mg/1mL Resulting solution is 100mcg/10mL (10mcg/mL) Epinephrine Admin 0.5-2mL (5-20 mcg) Q2-5min PRN of above solution Doses last ≈ 10min If mixing not possible, give 0.5mL dose of pure cardiac epi (50mcg) DO NOT ADMINISTER 1mg EPI TO INDIVIDUALS NOT IN CARDIAC ARREST References Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. Journal of Cardiovascular Pharmacology and Therapeutics. 2015;20(3):249-260. doi:10.1177/1074248414559838 &#8617; Hollenberg SM. Vasoactive Drugs in Circulatory Shock. American Journal of Respiratory and Critical Care Medicine. 2011;183(7):847-855. doi:10.1164/rccm.201006-0972CI &#8617; &#8617;2 Overgaard CB, Džavík V. Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease. Circulation. 2008;118(10):1047-1056. doi:10.1161/CIRCULATIONAHA.107.728840 &#8617; Weingart S. Push-dose pressors for immediate blood pressure control. Clinical and Experimental Emergency Medicine. 2015;2(2):131-132. doi:10.15441/ceem.15.010 &#8617;",
    "tags": "",
    "url": "/peripheral_brain/drugClasses/pressors.html"
  }]};
